Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) shares reached a new 52-week low during trading on Monday . The company traded as low as C$0.73 and last traded at C$0.67, with a volume of 5107 shares traded. The stock had previously closed at C$0.71.
Aptose Biosciences Stock Down 1.5 %
The company has a debt-to-equity ratio of 670.80, a quick ratio of 5.41 and a current ratio of 0.97. The company has a market cap of C$11.95 million, a P/E ratio of -0.08 and a beta of 1.36. The stock has a 50 day moving average price of C$0.97 and a 200 day moving average price of C$1.66.
Aptose Biosciences (TSE:APS – Get Free Report) (NASDAQ:APTO) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported C($0.98) EPS for the quarter, topping the consensus estimate of C($1.12) by C$0.14. Research analysts expect that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- Technology Stocks Explained: Here’s What to Know About Tech
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 3 Stocks That Could Beat the September Blues
- What is a Secondary Public Offering? What Investors Need to Know
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
